Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

6 Feb 2008 07:01

Angle PLC06 February 2008 For Immediate Release 6 February 2008 ANGLE plc ('ANGLE' or the 'Company') ANGLE selected for Long-term Management Contract with London Development Agency Knowledge Connect Programme ANGLE plc (AIM:AGL), the intellectual property and technology commercialisationcompany, announces that it has been selected as a preferred bidder for a majornew management contract worth £3.7 million over the next three years. ANGLE has been selected by the London Development Agency (LDA), subject tocontract, for the delivery of the Knowledge Connect Programme. The KnowledgeConnect Programme aims to increase the level of business research anddevelopment in London by creating new collaborations between business and theLondon knowledge base, with a focus on enterprises that have not previouslyworked with this sector. This flagship Programme, a core part of the LDA's Knowledge Transfer Strategy,will engage with 1,600 businesses and involve ANGLE working intensively with 265businesses across London. The Programme is being established to raise theperformance and aspirations of London's businesses by providing effectivesupport for research and development, knowledge transfer and innovation acrossthe Capital. ANGLE was selected following a competitive tendering process on the basis of itsexperience in delivering similar business support programmes in London, UK wideand internationally. Additionally ANGLE has developed techniques which, it wasable to demonstrate, have secured successful knowledge transfer from academicand research institutions and have measurable business benefits for a wide rangeof small and medium sized enterprises (SMEs). Andrew Newland, Chief Executive of ANGLE, said: "This represents a major success for our Management services business andunderlines our strategy of focusing on long-term and profitable contracts. Inaddition to generating new revenue for ANGLE it also clearly illustrates theattraction of our business model for SMEs looking to develop and commercialisetheir IP. "We are delighted to have been selected to partner the London Development Agencyin this new project. Our team is looking forward to working with London'sbusinesses to help identify new opportunities and secure business growth throughknowledge transfer and innovation." Garth Selvey, Chairman of ANGLE, added: "This project adds to the strength of our Management services business, whichprovides the platform for ANGLE's ongoing operation. As stated in our InterimResults for the six months ended 31 October 2007 released on 31 January 2008,the Board believes that several of ANGLE's portfolio companies have thepotential to deliver substantial cash returns for shareholders." Enquiries:ANGLE plc +44 (0)1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.